Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
Nat Med
; 27(2): 256-263, 2021 02.
Article
in En
| MEDLINE
| ID: mdl-33558721
Full text:
1
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Ipilimumab
/
Nivolumab
/
Melanoma
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2021
Type:
Article